|MEDICAL INTERNATIONAL TECHNOLOGY, INC.UNAUDITED PRO FORMA CONDENSED FINANCIAL STATEMENTSFOR THE YEAR ENDED SEPTEMBER 30, 2006 AND NINE MONTHS ENDED JUNE 30, 2007
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------

The following unaudited pro forma condensed financial statements and related notes are presented to show the pro forma effects of the acquisition of 9139-2449 Quebec Inc., dba Scanview (Scanview) during the
third quarter of 2007 (Scanview transaction).

The pro forma condensed statements of operations are presented to show income from continuing operations as if the Scanview transaction occurred as of the beginning of each period presented. The pro forma condensed balance
sheet is based on the assumption that the Scanview transaction occurred effective June 30, 2007.

Pro forma data are based on assumptions and include adjustments as explained in the notes to the unaudited pro forma condensed financial statements. The pro forma data are not necessarily indicative of the financial results
that would have been attained had the Scanview transaction occurred on the dates referenced above and should not be viewed as indicative of operations in future periods. The unaudited pro forma condensed financial statements should be read in
conjunction with notes thereto, Medical International Technology, Inc.s Annual Report on Form 10-KSB for the year ended September 30, 2006 and its Quarterly Report on Form 10-QSB for the quarter ended June 30, 2007.

1

---



|MEDICAL INTERNATIONAL TECHNOLOGY, INC.PRO FORMA FINANCIAL STATEMENTS(Unaudited)INDEX
|------------------------------------------------------------------------------------

|                                                                          |  | Page  
|------------------------------------------------------------------------- |  | ------
|                                                                          |  | Number
|Condensed Statement of Operations for the Year Ended September 30, 2006   |  | 3     
|Condensed Statement of Operations for the Nine Months Ended June 30, 2007 |  | 4     
|Condensed Balance Sheet June 30, 2007                                     |  | 5     
|Notes to the audited pro forma condensed financial statements             |  | 6     

2

---



|MEDICAL INTERNATIONAL TECHNOLOGY,INC.ANDSUBSIDIARYUNAUDITEDPROFORMACONDENSEDSTATEMENT OFOPERATIONSFORTHEYEARENDEDSEPTEMBER30,2006
|---------------------------------------------------------------------------------------------------------------------------------

|                                     |  |              |  | MIT        |  | Scanview    |  | Proforma |  |              |  |          
|------------------------------------ |  | ------------ |  | ---------- |  | ----------- |  | -------- |  | ------------ |  | ---------
|                                     |  | Historical   |  | Historical |  | Adjustments |  | Proforma
|                                     |  |              |  |            |  |             |  |         
|Sales                                |  | $ 270,452    |  | $ 86,884   |  | $           |  | -        |  | $ 357,336   
|Cost of sales                        |  |              |  | 181,599    |  | 33,838      |  |          |  | -            |  | 215,437  
|                                     |  |              |  |            |  |             |  |          |  |              |  |          
|Gross profit                         |  |              |  | 88,853     |  | 53,046      |  |          |  | -            |  | 141,899  
|Research and development costs       |  |              |  | 442,916    |  | 119,744     |  |          |  | -            |  | 562,660  
|Selling, general & administrative    |  |              |  | 1,125,042  |  | 41,978      |  |          |  | -            |  | 1,167,020
|                                     |  |              |  |            |  |             |  |          |  |              |  |          
|Total operating expenses             |  |              |  | 1,567,958  |  | 161,722     |  |          |  | -            |  | 1,729,680
|                                     |  |              |  |            |  |             |  |          |  |              |  |          
|Loss from operations                 |  | (1,479,105)  |  | (108,676)  |  |             |  | -        |  | (1,587,781) 
|Other income (expense)               |  |              |  |            |  |             |  |          |  |              |  |          
|Interest income                      |  |              |  | 728        |  | -           |  |          |  | -            |  | 728      
|Interest expense                     |  |              |  | (31,256)   |  | (7,286)     |  |          |  | -            |  | (38,542) 
|                                     |  |              |  |            |  |             |  |          |  |              |  |          
|Total other income (expense)         |  |              |  | (30,528)   |  | (7,286)     |  |          |  | -            |  | (37,814) 
|                                     |  |              |  |            |  |             |  |          |  |              |  |          
|Net loss                             |  | $(1,509,633) |  | $(115,962) |  | $           |  | -        |  | $(1,625,595)
|                                     |  |              |  |            |  |             |  |          |  |             
|Basic and diluted net loss per share |  | $            |  | (0.11)     |  |             |  |          |  |              |  | $ (0.12) 
|                                     |  |              |  |            |  |             |  |          |  |              |  |          
|Weighted average shares outstanding  |  | 13,367,737   |  |            |  |             |  |          |  | 13,367,737  
|                                     |  |              |  |            |  |             |  |          |  |             

|The accompanying notes are an integral part of the unaudited pro forma condensed financial statements.3
|-------------------------------------------------------------------------------------------------------

---



|MEDICAL INTERNATIONAL TECHNOLOGY,INC.ANDSUBSIDIARYUNAUDITEDPROFORMACONDENSEDSTATEMENT OFOPERATIONSFORTHE NINEMONTHSENDED JUNE30,2007
|------------------------------------------------------------------------------------------------------------------------------------

|                                     |  | MIT        |  | Scanview   |  | Proforma    |  |          |  |           
|------------------------------------ |  | ---------- |  | ---------- |  | ----------- |  | -------- |  | ----------
|                                     |  | Historical |  | Historical |  | Adjustments |  | Proforma
|                                     |  |            |  |            |  |             |  |         
|Sales                                |  | $ 150,630  |  | $ 78,487   |  | $           |  | -        |  | $         
|Cost of sales                        |  | 58,151     |  | 15,769     |  |             |  | -        |  |           
|                                     |  |            |  |            |  |             |  |          |  |           
|Gross profit                         |  | 92,479     |  | 62,718     |  |             |  | -        |  |           
|Research and development costs       |  | 126,255    |  | 26,938     |  |             |  | -        |  |           
|Selling, general & administrative    |  | 508,407    |  | 52,930     |  |             |  | -        |  |           
|                                     |  |            |  |            |  |             |  |          |  |           
|Total operating expenses             |  | 634,662    |  | 79,868     |  |             |  | -        |  |           
|                                     |  |            |  |            |  |             |  |          |  |           
|Loss from operations                 |  | (542,183)  |  | (17,150)   |  |             |  | -        |  |           
|Other income (expense)               |  |            |  |            |  |             |  |          |  |           
|Interest income                      |  | -          |  | -          |  |             |  | -        |  |           
|Interest expense                     |  | (56,812)   |  | (4,118)    |  |             |  | -        |  |           
|                                     |  |            |  |            |  |             |  |          |  |           
|Total other income (expense)         |  | (56,812)   |  | (4,118)    |  |             |  | -        |  |           
|                                     |  |            |  |            |  |             |  |          |  |           
|Net loss                             |  | $(598,995) |  | $(21,268)  |  | $           |  | -        |  | $         
|                                     |  |            |  |            |  |             |  |          |  |           
|Basic and diluted net loss per share |  | $ (0.03)   |  |            |  |             |  |          |  | $         
|                                     |  |            |  |            |  |             |  |          |  |           
|Weighted average shares outstanding  |  | 18,184,197 |  |            |  |             |  |          |  | 18,184,197
|                                     |  |            |  |            |  |             |  |          |  |           

|The accompanying notes are an integral part of the unaudited pro forma condensed financial statements.4
|-------------------------------------------------------------------------------------------------------

---



|MEDICAL INTERNATIONAL TECHNOLOGY,INC.ANDSUBSIDIARYUNAUDITEDPROFORMACONDENSEDBALANCESHEETJUNE30,2007
|---------------------------------------------------------------------------------------------------

|                                                             |  |            |  | MIT        |  | Scanview    |  | Proforma |  |   |  |         
|------------------------------------------------------------ |  | ---------- |  | ---------- |  | ----------- |  | -------- |  | - |  | --------
|                                                             |  | Historical |  | Historical |  | Adjustments |  | Proforma
|                                                             |  |            |  |            |  |             |  |         
|Assets                                                       |  |            |  |            |  |             |  |          |  |   |  |         
|                                                            
|Current assets                                               |  |            |  |            |  |             |  |          |  |   |  |         
|Cash                                                         |  | $          |  | 307        |  | $           |  | 820      |  |   |  |         
|Receivables <c>                                              |  |            |  | 96,282     |  |             |  | 48,429   |  |   |  | (15,345)
|Inventories                                                  |  |            |  | 73,051     |  |             |  | 67,334   |  |   |  |         
|Other current assets                                         |  |            |  | 60,643     |  |             |  | -        |  |   |  |         
|                                                             |  |            |  |            |  |             |  |          |  |   |  |         
|Total current assets                                         |  |            |  | 230,283    |  |             |  | 116,583  |  |   |  | (15,345)
|                                                            
|Property and equipment, net                                  |  |            |  | 74,761     |  |             |  | 73,637   |  |   |  |         
|                                                            
|Patents                                                      |  |            |  | 1,216      |  |             |  | -        |  |   |  |         
|Intangible asset <b>                                         |  |            |  | -          |  |             |  | -        |  |   |  | 131,382 
|                                                             |  |            |  |            |  |             |  |          |  |   |  |         
|                                                            
|Total assets                                                 |  | $          |  | 306,260    |  | $           |  | 190,220  |  | $ |  | 116,037 
|                                                             |  |            |  |            |  |             |  |          |  |   |  |         
|                                                            
|Liabilities and Stockholders' Equity                         |  |            |  |            |  |             |  |          |  |   |  |         
|                                                            
|Current liabilities                                          |  |            |  |            |  |             |  |          |  |   |  |         
|Unearned income                                              |  | $          |  | 89,314     |  | $           |  | -        |  |   |  |         
|Advances from MIT <c>                                        |  |            |  | -          |  |             |  | 15,345   |  |   |  | (15,345)
|Accounts payable and accrued interest                        |  |            |  | 682,954    |  |             |  | 78,693   |  |   |  |         
|                                                             |  |            |  |            |  |             |  |          |  |   |  |         
|Total current liabilities                                    |  |            |  | 772,268    |  |             |  | 94,038   |  |   |  | (15,345)
|                                                            
|Long-term debt                                               |  |            |  | -          |  |             |  | 52,564   |  |   |  | -       
|Stockholders' Equity <a>                                     |  |            |  | (466,008)  |  |             |  | 43,618   |  |   |  | 175,000 
|<b>                                                          |  |            |  |            |  |             |  |          |  |   |  | (43,618)
|                                                             |  |            |  |            |  |             |  |          |  |   |  | -       
|                                                             |  |            |  |            |  |             |  |          |  |   |  |         
|                                                            
|Total liabilities and stockholders' equity                   |  | $          |  | 306,260    |  | $           |  | 190,220  |  | $ |  | 116,037 
|                                                             |  |            |  |            |  |             |  |          |  |   |  |         
|                                                            
|<a>, <b>, and <c>: see proforma adjustment notes a, b, and c |  |            |  |            |  |             |  |          |  |  

|The accompanying notes are an integral part of the unaudited pro forma condensed financial statements.5
|-------------------------------------------------------------------------------------------------------

---



|MEDICAL INTERNATIONAL TECHNOLOGY,INC.ANDSUBSIDIARYNOTESTOUNAUDITEDPROFORMACONDENSEDFINANCIALSTATEMENTS
|------------------------------------------------------------------------------------------------------

Basis of Presentation

The unaudited pro forma condensed statement of operations for the year ended September 30, 2006, is based on the audited financial statements of Medical International Technology, Inc. (MIT) and Scanview for the
year ended September 30, 2006, and the adjustments and assumptions described below.

The unaudited pro forma condensed statement of operations for the nine months ended June 30, 2007, and the unaudited pro forma condensed balance sheet as of June 30, 2007, are based on the unaudited financial statements of
MIT and Scanview as of and for the nine months ended June 30, 2007, and the adjustments and assumptions described below.

Pro forma adjustments:

The unaudited pro forma balance sheet reflects the following adjustments associated with the Scanview transaction as of June 30, 2007.

|a. | Record the issuance of 2,500,000 shares of common stocks of MIT for the 100% equity interest of                                                                                                                                                                                                                                                                                                                                                                                                                                                               
|-- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|  
|   | Scanview and assumed liabilities from the Scanview transaction. The price used for the acquisition was the adjusted average closing share price of our stock for the week prior and week after the closing date, or $0.07
per share, which makes the fair value of the transaction $175,000. Accordingly, the weighted average number of common shares outstanding for the year ended September 30, 2006 and for the nine months ended June 30, 2007, for the purpose of the
pro forma financial statements is 13,367,737 and 18,184,197 shares, respectively.
|  
|b. | Record the intangible intellectual asset arising from the Scanview transaction of US$131,382 and the elimination of Scanviews retained earnings of US$43,618                                                                                                                                                                                                                                                                                                                                                                                                 
|  
|c. | Record the elimination of US$15,345 advances from MIT to Scanview.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
|  

6

---